To view this email as a web page, click here

Today's Rundown

Featured Story

Celltrion taps Intract Pharma to develop world's first oral Remicade biosimilar

Since the launch of the first Remicade biosimilar in 2016, drug giants like Pfizer and Amgen have made their own to contributions the lucrative market. Now, one company is looking to round out its subcutaneous and IV analogues with a third, oral tablet formulation that patients can take at home. 

read more

Top Stories

Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus

Otsuka's $15 million offer to buy up now-bankrupt Proteus Digital Health has been cleared by a U.S. court despite a group of investors, including Novartis, calling the deal "nothing more than a giveaway” to an insider.

read more

Union, TFF team up to fight COVID-19 with inhaled tapeworm med

When COVID-19 struck, Austin, Texas-based biotech TFF Pharmaceuticals tapped its thin-film freezing technology—used to make dry powder versions of non-water soluble drugs—to develop inhaled forms of the tapeworm drug niclosamide. Now, TFF has tied up with Danish drugmaker Union Pharmaceuticals in a $210 million licensing deal for access to the niclosamide tech.

read more

Sulzer, in push for convenient dosing, snares Swiss self-injection developer Haselmeier for $118M

Swiss engineering firm Sulzer is looking to build out its healthcare offerings through the purchase of applicator device maker Haselmeier in a deal worth $118 million. Expected to close on October 1, the tie up would grant Sulzer access to Haselmeier's drug delivery devices, including self-injection pens for reproductive health, growth disorders, osteoporosis and diabetes.

read more

Enrollment Showcase

Bioscience Certificate Pathways Advancing Knowledge, Skills, & Careers

Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more.

Resources

Whitepaper: Top 7 Data Points from Medical Claim Forms to Drive Market Development

Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information.

Whitepaper: New data models to gain insight on medication adherence

Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization.

Report: Decentralized Trials - Where Does the Industry Stand?

Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual."

Whitepaper: New data models to gain insight on medication adherence

Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization.

Whitepaper: Navigating the Changing Clinical Trial Landscape

The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need.

Whitepaper: Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs

How to select the right dosage form for your Phase I clinical supply.

Whitepaper: Quality by Design: A Holistic Approach to Drug Development

Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker.

Webcast: DRUG ABUSE LIABILITY ASSESSMENT: Are you taking an integrated approach?

Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment

Executive Summary: Keys to a Successful Rapid Commercial Launch

Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better.

Whitepaper: Reducing the Complexity and Costs of Channel Planning and Logistics

Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients.

Whitepaper: More Powerful Analytics Capabilities

Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI.

eBook: Navigating the Insulin Affordability Act

Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

Paid Marketplace: Want to Change the World? Join the Phlow Corp. Team

Interested in putting patients, people, and planet over profit in a fast-paced environment? Please Apply: VP of Integrated Supply Chain and VP of Manufacturing, Science, & Technology

Whitepaper: Learn How to Navigate Pediatric Clinical Trials Under the New RACE Act

Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need.

Video: How to Put Real World Data into Action

Accurate, timely insights are everything. Whatever the question, the answers demand real world data you can trust. Healthy data advances reliable insights, and takes the error out of AI. Healthy data is not just useable, but invaluable. Healthy data starts with InterSystems.

Events